news

BHI Therapeutic Sciences studies are registered at the clinical trial registries

Posted by on Aug 29, 2019 in news | 0 comments

Clinical trials are research investigations that play an important role in the development of health information and research for public health care. Clinical trials guiding principles are based on maximum benefit and minimal risk to the participants enrolled in a study. According to the Ethical Principles for Medical Research Involving Human Subjects (World Medical Association Declaration of Helsinki), “every clinical trial must be registered in a publicly accessible database before recruitment of first subject”. The main registry purpose is to fulfill ethical obligations to...

Read More

BHI THERAPEUTIC SCIENCES ABSTRACT TO BE PRESENTED AT GERMAN STEM CELL CONFERENCE

Posted by on Aug 29, 2019 in news | 0 comments

BHI Therapeutic Sciences (BHITS) has been invited to present its abstract, “A retrospective chart review study of allogeneic umbilical cord blood mononuclear cell therapy for stroke,” at the German Stem Cell Network;s 7th Annual GSCN Conference being held Sept. 23-25 at the Max Delbruck Center for Molecular Medicine in Berlin.  Marina Manvelyan, PhD., BHITS Clinical Research Scientist said: “We are excited to be part of this gathering to share knowledge with other scientists across the globe. We look forward to learning more about what our colleagues...

Read More

BHI Therapeutic Sciences Inc. Notified by FDA that is can proceed with New Drug Clinical Trial for Acute Ischemic Stroke

Posted by on Jun 5, 2018 in news | 0 comments

BHI Therapeutic Sciences (BHITS), a leader in stem cell therapy and research utilizing human umbilical cord blood, announced today that the company has been notified by the Food and Drug Administration (FDA) that its Investigational New Drug (IND) application to allow for the initiation of a clinical study of an FDA-approved cell therapy (HCP, cord blood) for treatment of acute ischemic stroke may proceed.   Phase 1/2 Study entitled “Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects with Acute Ischemic Stroke” is a prospective, open-label, single-center,...

Read More

Professional Physique Champion is named Ambassador for BHI Slovakia.

Posted by on Jun 5, 2018 in news | 0 comments

Anton Antipov, an International Federation of Body Building and Fitness (IFBB) professional physique champion and fitness model, recently visited BHI Slovakia, stem cell research and treatment center, where he was named an ambassador for the healthcare organization. Mr. Antipov is an accomplished competitor and New York-based model, who has made a name for himself on social media and in the fitness industry. Growing up in Belarus, Mr. Antipov never had access to a gym, but he played sports to stay fit. After his family immigrated to America in the 1990s, Mr. Antipov had his first experience...

Read More

Stem Cells: The Next Frontier documentary screening for investors in NYC.

Posted by on Jun 5, 2018 in news | 0 comments

BHI Therapeutic Sciences (BHITS) and Brian Mehling, M.D. hosted a private screening of Stem Cells: The Next Frontier on Tuesday, February 13 in New York. The evening included a Q & A session and information on how to participate by becoming an investor to make these life-saving stem cells therapies more accessible to patients across the globe. “At BHITS, our philosophy is that stem cells are the future of medicine and we are excited to share our ideas with the general public and investors. BHITS is pioneering ethical, effective, safe and affordable stem cell treatment therapies...

Read More

BHI Therapeutic Sciences attended the World Economic Forum in Davos, Switzerland.

Posted by on Jun 5, 2018 in news | 0 comments

The 2018 World Economic Forum (WEF) in Davos explored the ideas, innovations and discoveries that are reshaping our world by working closely with those in the vanguard of change from such fields as the arts, culture, engineering, media, medicine, science, and technology. During the past few days, the US-based company BHI Therapeutic Sciences (BHITS) represented by Brian Mehling, MD, Founder and Chief Medical Officer; Klara Doert, President of International Business Development; Katarina Novakova, Director of Relations; and Manuel McDonald, International Consultant attended the annual meeting...

Read More